Group 1 - China Energy Construction won a major coal-fired power project with a bid amount of approximately 14.586 billion yuan, involving six 660 MW supercritical coal-fired generating units and supporting environmental facilities, with a total construction period of about 36.5 months [1] - Taiji Industry plans to repurchase company shares with a total amount not less than 1 billion yuan and not exceeding 1.2 billion yuan, with a maximum repurchase price of 10.38 yuan per share [1] - Youxun Technology won a project from State Grid with a bid amount of approximately 176 million yuan, accounting for 17.44% of the company's audited revenue for 2024 [2] Group 2 - Daili New Materials established an investment fund with a total subscribed capital of 163.3 million yuan, with Daili contributing 10 million yuan, accounting for 6.12% of the fund [4] - Wanyi Technology received a government subsidy of 2.3475 million yuan, which has been confirmed and classified according to relevant accounting standards [6] - Anke Biotech received a drug registration certificate for Acetate Atosiban Injection, which is used for treating preterm labor [7] Group 3 - Renfu Pharmaceutical received a drug registration certificate for Progesterone Soft Capsules, which are used to treat functional disorders caused by progesterone deficiency [9] - Linyang Energy is a recommended candidate for a major contract with State Grid, with a total expected bid amount of approximately 165 million yuan [11] - Hongtian Technology plans to invest 200 million to 300 million yuan to establish a wholly-owned subsidiary in Gansu Province [28] Group 4 - Hunan Xiang Electric received a total of 40 million yuan in government subsidies, which accounts for 16.07% of the company's audited net profit for 2024 [44] - Nengke Technology plans to repurchase shares with a total amount not less than 10 million yuan and not exceeding 20 million yuan, with a maximum repurchase price of 43.00 yuan per share [46] - Xiamen XGMA received 10 million yuan in historical debt repayment, which is expected to increase the company's net profit for 2025 by 3.186 million yuan [48]

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-041 黑龙江珍宝岛药业股份有限公司 关于全资子公司收购其控股子公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 黑龙江珍宝岛药业股份有限公司（以下简称"公司"）全资子公司亳州 中药材商品交易中心有限公司（以下简称"亳州交易中心"）拟收购其控股子公 司贵州神农谷健康产业发展有限公司（以下简称"贵州神农谷"）49%的股权。 收购完成后，贵州神农谷将成为亳州交易中心的全资子公司。 1、企业名称：贵州省农业农村现代化发展股权投资基金合伙企业（有限合 伙） 2、统一社会信用代码：91520115MAAKDYDC8Q 3、成立时间：2021 年 3 月 29 日 4、出资额：1,800,100 万元人民币 ● 本次投资金额为贵州省农业农村现代化发展股权投资基金合伙企业（有 限合伙）（以下简称"贵州农业发展基金"）投资本金 49,000 万元人民币加投 资期内基金监管户活期存款利息。 一、交易概述 公司全资子公司亳州交易中心持有控股子公司贵 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-040 黑龙江珍宝岛药业股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，黑龙江珍宝岛药业股份有限公司（以下简称"公司"）收到国家药品 监督管理局颁发的《药物临床试验批准通知书》，现就相关情况公告如下： 一、药品的基本情况 药品名称：复方芩兰口服液 通知书编号：2025LP01436 受理号：CYZB2500437 药品注册标准编号：《中国药典》2020 年版一部 注册分类：补充申请 剂型：合剂 规格：每支装 10ml 生产企业：黑龙江珍宝岛药业股份有限公司、黑龙江羽迪药业有限责任公司 药品批准文号：国药准字 Z20026049 药品批准文号有效期：至 2030 年 06 月 20 日 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 3 月 13 日受理的复方芩兰口服液（CYZB2500437）临床试验申请符合药品注 册的有关要求，在进一步完善临床试验方案的基础上，同意本品开展用 ...

Core Viewpoint - The company, Zhenbaodao, announced that its wholly-owned subsidiary, Bozhou Chinese Medicine Material Trading Center Co., Ltd., plans to acquire a 49% stake in its controlling subsidiary, Guizhou Shennong Valley, for a total price of 49 million RMB plus interest from the fund's regulatory account during the investment period [1] Group 1 - The acquisition will result in Bozhou Trading Center holding 100% of Guizhou Shennong Valley after the transaction is completed [1] - The transaction does not constitute a related party transaction or a major asset restructuring, and therefore does not require approval from the company's board of directors or shareholders' meeting [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of a new herbal medicine, Compound Qilan Oral Solution, aimed at treating children aged 4-12 with external wind-heat symptoms [1] Group 1: Product Development - The Compound Qilan Oral Solution is an independently developed traditional Chinese medicine by the company, derived from the classic formula "Yinqiao San" from the Qing Dynasty [1] - This product is part of the company's respiratory disease medication line and represents one of its key offerings [1] Group 2: Financial Aspects - The projected sales revenue for the Compound Qilan Oral Solution in 2024 is estimated to be 212 million yuan [1] - The company has invested approximately 15 million yuan in research and development for this product to date [1]

Core Viewpoint - The company received a shareholder inquiry letter from the China Securities Investor Service Center regarding compliance with disclosure and approval procedures related to a significant transaction that generated substantial profits exceeding regulatory thresholds [1][2][3]. Group 1: Transaction Details - The company reported a financial net gain of 420 million yuan from a transaction, which represents over 50% of the company's audited net profit of 185 million yuan for 2022 [1][3]. - The transaction's total amount was 425 million yuan, and it was noted that the transaction's profit exceeded the regulatory requirement of 5 million yuan [3]. Group 2: Regulatory Compliance Issues - The company faced scrutiny due to a warning letter from the Heilongjiang Securities Regulatory Bureau, which identified non-operational fund occupation by the controlling shareholder amounting to 80 million yuan, returned in February 2024 [2]. - The company failed to timely disclose and seek shareholder approval for the transaction, which was only addressed in a board meeting held on April 1, 2025, with subsequent disclosure on April 2, 2025 [3]. Group 3: Measures for Improvement - The company has implemented a comprehensive review and revision of its information disclosure management system to ensure compliance with standards, processes, and responsibilities [4]. - Internal controls have been strengthened, emphasizing the importance of compliance with disclosure regulations and enhancing the effectiveness of internal governance [5][6]. - The company has initiated training programs for personnel involved in information disclosure to improve their understanding of legal requirements and enhance compliance awareness [6][7].

关于中证中小投资者服务中心《股东质询函》的 回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-039 黑龙江珍宝岛药业股份有限公司 黑龙江珍宝岛药业股份有限公司（以下简称"公司"）近日收到中证中小投 资者服务中心（以下简称"投服中心"）的《股东质询函》（投服中心行权函【2025】 11 号），投服中心对公司 2023 年 8 月转让子公司股权并于近期补充披露的违规 操作事项提出质询。现就相关问题回复如下： 一、《上海证券交易所股票上市规则》(2023 年 2 月修订)6.1.3 条规定,交 易产生的利润占上市公司最近一个会计年度经审计净利润的 50%以上，且绝对金 额超过 500 万元，上市公司除应当及时披露外，还应当提交股东大会审议。根 据公告披露，本次交易完成后获得财务净收益 4.2 亿元,2022 年，你公司归属于 上市公司股东的净利润为 1.85 亿元,交易产生的利润占最近一个会计年度经审 计净利润的 50%以上，且绝对金额超过 500 万元。 ...

Core Viewpoint - The 90th National Pharmaceutical Trade Fair showcased Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., highlighting its brand, high-value product matrix, and ecological win-win philosophy [3][4] Group 1: Product Showcase - Zhenbaodao Pharmaceutical exhibited high-quality product lines focusing on cardiovascular, respiratory, and anti-infection treatment areas, including key products like Injection Blood Setong 100mg and Xuechuang Capsule [3] - The company has developed a dual-driven system of "Traditional Chinese Medicine + Chemical Medicine," featuring products such as Compound Qilan Oral Liquid and Injection Ammonium Bromide [3] Group 2: Marketing Strategy - The company emphasized its 2025 "Guangshen Tuo" marketing strategy, which segments regional markets based on product attributes and promotes a model of "recruiting merchants, finding merchants, and servicing merchants" to enhance terminal coverage and sales efficiency [4] - Zhenbaodao Pharmaceutical established a three-tier academic promotion system, integrating medical, market, and data teams to monitor industry trends and provide precise marketing strategies [4] Group 3: Collaborative Ecosystem - The participation in the trade fair demonstrated the company's competitive product pipeline and industrial layout, aiming to build a comprehensive ecosystem of strategic collaboration, resource sharing, and value co-creation [4] - The company plans to continue driving innovation and collaboration, positioning itself to lead the pharmaceutical industry towards higher value creation [4]

Core Insights - The company is advancing its strategic layout and business progress through product pipeline expansion, technological innovation, and industrial collaboration, showcasing strong resilience and growth potential [1] Group 1: Product Innovation and Core Competitiveness - The company has been upgrading its product pipeline and increasing R&D investment, with its subsidiary obtaining approval for 16 chemical drug listings, covering major diseases with significant market potential [2] - The introduction of AI visual inspection technology for production monitoring and the development of a smart trading platform for traditional Chinese medicine (TCM) are enhancing the company's competitive edge [2] Group 2: Industry Ecosystem Development - The company is promoting industrial cooperation projects to boost local economic development, linking over 10,000 quality herbal merchants through its trading center [3] - A strategic partnership with a leading TCM company has strengthened the supply capacity of herbal medicines, enhancing the trading center's competitiveness [3] Group 3: Digital Transformation and Supply Chain Management - The company initiated the Guizhou Shennong Valley project to create a standardized, digitalized, and networked industry ecosystem, establishing 6 standardized planting bases covering 4,400 acres [4] - The implementation of a digital management platform ensures traceability and quality control of herbal medicines, benefiting both product quality and farmer income [4] Group 4: Brand Empowerment and Market Expansion - The company has developed a comprehensive marketing system to enhance brand influence, showcasing its diverse product pipeline at national trade events [5] - Core products have excelled in national TCM procurement, reinforcing market position through quality advantages and innovative strategies [5] Group 5: Sustainable Development Strategy - The company has proposed a dual-engine strategy focusing on "scientific innovation and resource aggregation," aiming to enhance evidence-based medicine research and smart manufacturing [6] - The goal is to modernize and internationalize traditional Chinese medicine, targeting a marketing scale of 10 billion and creating a health industry ecosystem [6] Group 6: Overall Growth Path - The company demonstrates a clear growth trajectory and momentum through strategic focus, product innovation, and ecosystem collaboration, addressing market concerns amid regulatory challenges [7][8]

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-038 黑龙江珍宝岛药业股份有限公司 关于为全资子公司银行贷款展期提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●被担保人名称：哈尔滨珍宝制药有限公司（以下简称"哈珍宝"），系黑龙 江珍宝岛药业股份有限公司（以下简称"公司"）的全资子公司。 ●本次担保金额为不超过人民币 1.70 亿元，截至公告披露日，公司已实际 为哈珍宝提供的担保余额为人民币 9.21 亿元（含本次担保）。 ●截至本公告披露日，公司实际对外担保总额人民币 16.01 亿元（含本次担 保），全部是公司对全资子公司进行的担保。 ●本次担保无反担保。 ●公司无对外担保逾期的情况。 公司全资子公司哈珍宝于 2024 年 5 月 15 日向哈尔滨联合农村商业银行股份 有限公司呼兰支行（以下简称"哈联合农村商业银行"）申请 1.70 亿元人民币贷 款，贷款期限为 12 个月，公司为哈珍宝上述贷款事项提供连带责任保证担保。 （具体内容详见公司于 2024 年 5 月 16 ...